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The IFN-induced human myxovirus resistance protein A
(MxA) exhibits a broad antiviral activity against many viruses,
including influenza A virus (IAV). MxA belongs to the family of
dynamin-like GTPases and assembles in vitro into dimers,
tetramers, and oligomeric ring-like structures. The molecular
mechanism of action remains to be elucidated. Furthermore, it
is not clear whether MxA exerts its antiviral activity in a mono-
meric and/ormultimeric form. Using a set ofMxAmutants that
form complexes with defined stoichiometry, we observed that,
in the presence of guanosine 5-O-(thiotriphosphate), purified
MxA disassembled into tetramers and dimers. Dimeric forms
did not further disassemble into monomers. Infection experi-
ments revealed that besides wild-typeMxA, dimeric andmono-
meric variants of MxA also efficiently restricted IAV at a repli-
cation step after primary transcription. Moreover, only dimeric
MxA was able to form stable complexes with the nucleoprotein
(NP) of IAV. MxA interacted with NP independently of other
viral components. Interestingly, the dimeric form of MxA was
able to efficiently bind toNP from severalMxA-sensitive strains
but interactedmuchmoreweaklywithNP from theMxA-resist-
ant PR8 strain derived from the H1N1 1918 lineage. Taken
together, these data suggest that, during infection, a fraction of
MxA disassembles into dimers that bind to NP synthesized fol-
lowing primary transcription in the cytoplasm, thereby prevent-
ing viral replication.
The interferon system plays a pivotal role in the defense
against viral infection. Interferons type I and III induce the
expression of more than 300 proteins, many of them exhibiting
intrinsic antiviral activity (1–3). The human myxovirus resis-
tance protein A (MxA)3 protein is induced exclusively by type I
and type III interferons and restricts the replication of a large
variety of RNA and DNA viruses (reviewed in Ref. 4). Mx
proteins are members of the dynamin superfamily of large
GTPases. They contain an amino-terminal globular GTPase
(G) domain and a carboxy-terminal stalk domain (5, 6). The
stalk domain harbors the GTPase effector domain and addi-
tional structural elements, including the L4 loop required for
antiviral activity and target specificity (7–9). The G and stalk
domains are connected via the bundle signaling element (BSE),
which strongly resembles the BSE responsible for intramolecu-
lar signaling in dynamin (10).Mx proteins exhibit a high intrin-
sic rate of GTP hydrolysis, although the affinity to GTP is weak
(11). Moreover, the human MxA protein forms dimers and
tetramers and has the capacity to form higher oligomeric ring-
like structures through a series of intra- and intermolecular
interactions (5, 6, 12, 13). Introduction of mutations into the
interfaces of the intermolecular interaction sites or hinge
regions of MxA prevents assembly into higher-order multim-
eric forms. These mutations lead to the formation of MxA into
tetramers, dimers, and monomers (5, 12).
So far, little is known about the molecular mechanism of
action of the human MxA protein. Previous studies have dem-
onstrated that GTP binding is required for its efficient antiviral
activity against vesicular stomatitis virus and IAV (6, 14). In the
case of IAV, several previous studies have demonstrated that
ectopic expression of the nucleocapsid protein (NP) or the po-
lymerase subunit 2 (PB2) of the virus partially abrogated the
antiviral activity ofmouseMx1 (15–17).Moreover, human IAV
strains are partially resistant to the activity of MxA, whereas
non-adapted avian IAV strains such as H5N1 are highly sensi-
tive to MxA. Recent findings indicate that resistance of human
IAV strains to the activity of MxA is determined by NP (18).
Adaptivemutations in a surface-exposed cluster of amino acids
have been identified to counteract the restriction by MxA (19,
20). So far, there is only little evidence for a physical interaction
betweenNPof IAVandMxA (21).Wehave shown recently that
MxA binds to UAP56, a DEAD-box helicase. UAP56 is also an
interaction partner of NP and is required for efficient replica-
tion of IAVand evasion of the IFN response (22–24). Therefore,
UAP56 may recruit MxA and NP to form a complex involving
all three proteins.
To date, it is not clear whether the assembly of MxA into
higher-ordered oligomeric structures is required to confer anti-
viralactivity.Severalpreviousstudieshaverevealedthatamono-
meric mutant of MxA (L612K) still exhibited a pronounced
antiviral activity against IAV and Thogotovirus and vesicular
stomatitis virus (6, 25–27). On the basis of these findings, we
previously proposed a model where newly synthesized MxA
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would assemble into higher-ordered oligomeric, preactivated
structures and would disassemble into antivirally active mono-
mers in response to a viral trigger in infected cells (6). On the
other hand, on the basis of the recently solved crystal structure
of MxA, Gao et al. (5, 12) proposed a model where MxA would
assemble into ring-like structures around incoming viral ribo-
nucleoprotein (vRNP) complexes. These ring-like structures
would then interfere with nuclear import and/or primary tran-
scription. However, previous studies with stable MxA-express-
ing cell lines have clearly demonstrated thatMxA inhibits an as
yet undefined cytoplasmic step of the IAV life cycle that follows
primary transcription (28).
To clarify this issue,we first evaluated in vitro the influence of
GTP binding on the assembly state of MxA and assessed vari-
ous interface and hinge mutants with defined monomeric or
multimeric forms for their antiviral activity and capacity to
interact with NP of IAV. The data indicate that, in the presence
of GTPS, recombinant MxA disassembles from higher-or-
dered oligomeric structures into tetramers and dimers. Con-
trary to previous reports byGao et al. (5, 12), dimeric andmono-
meric forms of MxA also exerted a pronounced antiviral
activity against avian IAV. Furthermore, only MxA in its
dimeric formwas able to form stable complexes with NP deriv-
ing fromMxA-sensitive IAV strains independent of other viral
components.
Experimental Procedures
Cells andViruses—Madin-Darby canine kidney cells, African
green monkey kidney (Vero) cells, HeLa cells, and HEK293T
cells (all from the ATCC, LGC Standards) were cultured in
growth medium consisting of Dulbecco’s modified Eagle’s
medium supplemented with 10% FCS, 1 Glutamax, and 1
penicillin/streptomycin (Invitrogen). Cells transiently express-
ing human MxA (wild type or variants) were generated by
transfecting the cells with pcDNA3.1()neo constructs coding
forMxAwild-type or mutant using JetPRIME (Polyplus Trans-
fection) according to the protocol of the manufacturer.
All infection experiments were carried out using A/Puerto
Rico/8/1934(H1N1) (PR8), pH1N1-NP(H5N1), A/seal/Mass/
1/1980(H7N7) (mouse-adapted mutant rSC35M), or A/FPV/
Dobson/1927(H7N7) (FPV). PR8, rSC35M, and FPV were pre-
pared from supernatants of virus-infectedMadin-Darby canine
kidney cells. The reassortant virus pH1N1-NP(H5N1) was pro-
vided by Martin Schwemmle and has been published before
(18). For infection, cells were kept in infection medium (Dul-
becco’s modified Eagle’s medium supplemented with 20 mM
Hepes, 0.2% BSA, 1 Glutamax, and 1 penicillin/streptomy-
cin (Invitrogen)). Unless indicated otherwise, cells were main-
tained at 37 °C in 5% CO2.
Plasmid Construction—The coding sequence of the MxA
cDNA used has been described previously (29). The cDNAs of
the MxA mutants MxA(T103A), MxA(R640A), MxA(L617D),
and MxA(M527D) have been described previously (5, 12, 26)
(provided byGeorg Kochs, Freiburg, Germany) andwere intro-
duced into the expression plasmids pQE30 (Qiagen) and
pcDNA3.1()neo (Invitrogen). The expression vectors for
Mx1 and Mx1(K49A) have been described previously (11).
Purification of His-tagged Recombinant Human MxA—400
ml of LB medium supplemented with 0.1% glucose, 100 g/ml
ampicillin, and 50 g/ml kanamycin was inoculated with Esch-
erichia coliDH5 transformed with pQE30-MxA (wild type or
variant) at an A600 of 0.1. The expression cultures were incu-
bated at 37 °C and 180 rpm until an A600 of 0.4–0.6 was
reached. The expression cultures were cooled to 19 °C and
induced with 45 M isopropyl--D-thiogalactopyranoside. At
19 °C and 180 rpm, the expression cultures were incubated
overnight. For harvesting, the expression cultures were centri-
fuged at 5000 g and 4 °C. The pellet was resuspended in lysis
buffer (50mMHepes (pH 7.5), 500mMNaCl, 5mMMgCl2, 0.5%
CHAPS, 5 mM -mercaptoethanol, 30 mM imidazole, Roche
Complete protease inhibitor mixture, and 1 mg/ml lysozyme)
and sonicated for 6 cycles of 10 pulses on ice. After centrifuga-
tion at 15,000  g and 4 °C, the soluble fraction was filtered
(pore size, 0.2 m) and incubated with lysis buffer equilibrated
with nickel-nitrilotriacetic acid Superflow (Qiagen) overnight
at 4 °C on a rotating wheel. The protein-loaded nickel-nitrilo-
triacetic acid was washed with 5 volumes of wash buffer I (50
mM Hepes (pH 7.5), 800 mM NaCl, 5 mM MgCl2, 0.5% CHAPS,
5 mM -mercaptoethanol, 1 mM ATP, and 30 mM imidazole)
and 5 volumes of wash buffer II (50mMHepes (pH 7.5), 200mM
KCl, 5 mMMgCl2, 0.5% CHAPS, 5mM -mercaptoethanol, and
80 mM imidazole). The His-tagged protein was eluted with 2.5
volumes of elution buffer (50 mM Hepes (pH 7.5), 200 mM KCl,
5 mM MgCl2, 0.5% CHAPS, 5 mM -mercaptoethanol, and 300
mM imidazole), and, subsequently, the buffer was exchanged
with storage buffer (50 mM Hepes (pH 7.5), 200 mM KCl, 5 mM
MgCl2, 5 mM -mercaptoethanol, and 20% glycerol) using dis-
posable PD-10 desalting columns (GE Healthcare Biosciences)
according to the protocol of the manufacturer. The samples
were stored at80 °C until further analysis.
GTPase Activity Analysis of Recombinant Human MxA—
The GTPase activity of purified recombinant MxA was deter-
mined by incubating 0.01, 0.1, 1, 10, and 100 g/ml purified
recombinant MxA sample with 10 M GTP and 0.1 M AMP-
PNP at 37 °C for 1 h. The sample was analyzed using the Tran-
screenerGDP assay (Belbrooks Lab) according to themanual of
themanufacturer. TheGTPase activitywas normalized to 100%
GDP conversion by incubating the reactionmixturewith 10M
GDP instead of GTP.
Size Exclusion Chromatography and Multi-angle Light Scat-
tering (SEC-MALS)—Purified recombinant human MxA sam-
ples were dialyzed against 50 mM Hepes (pH 7.5), 200 mM KCl,
5 mMMgCl2, and 0.75mMDTT overnight. Then 1mg/ml puri-
fied recombinant human MxA samples were incubated with
either 1mMGTPS or buffer at 37 °C for 1 h prior to analysis by
SEC-MALS. To determine the exactmolarmass of each recom-
binant humanMxAconstruct, SEC-MALSmeasurementswere
performed as follows. 100 l of the sample was loaded on a
24-ml Superdex 100 column (GE Healthcare Biosciences) with
a flow rate of 0.5 ml/min and 50 mM Hepes (pH 7.5), 200 mM
KCl, 5 mM MgCl2, and 0.75 mM DTT as running buffer. The
chromatographwas calculated according to theUV absorbance
(280 nm). The SEC was followed by miniDAWN three-angle
light-scattering detector (Wyatt Technology) and Optilab rEX
differential refractometer (Wyatt Technology) analyses. The
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calculation of the molar mass was determined by the scattered
light (Rayleigh ratio)measured by theMALS detector. The data
were recorded and analyzed using the ASTRA V software
(Wyatt Technology).
Split-GFP Complementation Assay—The cloning of the vec-
tors pCDNA3.1-GFP(158–238) and pCDNA3.1-GFP(1–157)
has been described before (30). To clone theMxAwild type and
variants in either of these vectors, the open reading frames of
those constructs were amplified using PCR and subsequently
introduced into the multiple cloning site located at the C ter-
minus of the GFP fragment. HeLa cells were transfected with
these constructs using Viafect (Promega) according to the pro-
tocol of the manufacturer. 24 h post-transfection, cells were
incubated at 27 °C for 2 h before fixation with 3% paraformal-
dehyde. After permeabilization with 0.5% Triton X-100, cells
were stained with a mouse monoclonal MxA antibody (HB143
supernatant, in-house). Samples were mounted in DAPI con-
taining mounting medium (Fluoromount, Southern Biotech)
and consequently analyzed by confocal laser-scanning micros-
copy (CLSM Leica SP5, Leica Microsystems) using the LAS AF
software (Leica).
Non-denaturing PAGE—Non-denaturing PAGE was per-
formed as described before with a fewmodifications (31). Basi-
cally, Vero cells were grown in 10-cm dishes and transfected
with MxA coding plasmids. Cells were lysed (20 mM Tris-HCl
(pH 7.5), 150mMNaCl, 5mMMgCl2, 100M iodoacetamide, 50
mM NaF, 1 mM Na3VO4, 1% Nonidet P-40, 50 mM -glycero-
phosphate, and Roche Complete protease inhibitor mixture) in
the dark on ice for 30 min. To remove cell debris, lysates were
centrifuged at 13,000  g for 20 min at 4 °C. As described for
blue native PAGE (32), lysates were dialyzed against 20 mM
Tris-HCl (pH6.8), 10% glycerol, 0.1%CHAPS, and 0.5mMDTT
at 4 °C for 4 h using Slide-A-Lyzer MINI dialysis devices with a
10,000 cutoff (Thermo Scientific). Dialyzed samples were cen-
trifuged at 13,000  g and 4 °C for 20 min before loading on a
precast 4–16% TGXTM gradient gel (Bio-Rad). Using 25 mM
Tris-HCl (pH 8.3), 192 mM glycine, 0.5 mM DTT, and 0.1%
CHAPS as running buffer, the gel was run at 4 °C with a con-
stant current of 25 mA for 4 h. The gel was incubated in 25 mM
Tris-HCl (pH 8.3), 192 mM glycine, and 0.1% SDS for 10 min
before Western blotting. Blots were stained for MxA (rabbit
anti-Mx1, Novus Biologicals, catalog no. H00004599_D01P).
The molecular weight was determined using nativeMARK
(Invitrogen).
Assay for Antiviral Activity (TCID50 perMilliliter)—The 50%
tissue culture infective dose (TCID50) was determined by infec-
tion ofHEK293T cells transiently expressingMxA (wild type or
variants) with a 10-fold serial dilution of pH1N1-NP(H5N1)
(virus stock, 1.64 108 TCID50/ml) at 37 °C for 24 h. Cells were
immunostained for NP using HB65 supernatant (ATCC). The
TCID50 permilliliterwas calculated according to themethodby
Reed and Muench (47).
Minimal Replicon Reconstitution Assay—The minimal repli-
con reconstitution assay has been described before (33). In a
24-well dish, HEK293T cells were co-transfected with 10 ng of
pcaggs-PB1, 10 ng of pcaggs-PB2, 10 ng of pcaggs-PA, 50 ng of
pcaggs-NP, and 50 ng of pPolI-FFluc-RT firefly luciferase
flanked by the non-coding regions of segment 8 of influenza A
virus using JetPEI (Polyplus Transfection). Also included in the
transfection mixture were 100 ng of the constitutively Renilla-
expressing plasmid pRL-SV40. Additionally, 200, 400, or 800 ng
of pcDNA3.1()neo MxA was added. To maintain constant
DNA levels, empty vector (pcDNA3.1()neo) was included in
the reactionmixture. All viral constructs were derived from the
A/Thailand/1/2004 (Kan-1) strain. 24 h post-transfection, cells
were assayed for luciferase activity using the Dual-Luciferase
assay (Promega). Transfection efficiencywas normalized by the
Renilla luciferase signal.
In the case of NP and PB2 plasmid titration, the amounts of
plasmids encodingMxA (200 ng) and mouseMx1 (45 ng) were
kept constant, whereas the amounts for the PB2 andNP coding
plasmids were increased gradually (NP: 50, 100, 200, 400, 800,
or 1600 ng; PB2: 10, 20, 40, 80, 160, or 320). To maintain a
constant amount of transfectedDNA, empty pcDNA3.1()neo
was used.
RT qPCR—HEK293T cells transiently expressing MxA (wild
type or variants) were grown in 6-well dishes and pretreated
with 10 M cycloheximide or solvent for 1 h at 37 °C before
infection with either pH1N1-NP(H5N1) or PR8 at m.o.i. 5 for
6 h. Total RNA was purified as follows. Cells were lysed in 500
l of TRIzol reagent (Invitrogen). 100 l of chloroform was
added to the lysates,mixed, and centrifuged at 13, 000 g for 15
min at 4 °C. After centrifugation, 600 l of the aqueous RNA-
containing phase was mixed with 600 l of 70% EtOH. The
resulting solution was transferred onto RNeasy spin columns
(Qiagen), and further RNA extraction steps were performed
according to the RNeasyMini Kit protocol (Qiagen). cDNAwas
synthesized using SuperScript III reverse transcriptase (Life
Technologies) according to the protocol of the manufacturer,
using oligo(dT)15 (Promega) as a primer. PB2 and GAPDH
transcripts were detected in an EvaGreen (Biotum)-based
qPCR reaction (denaturation, 95 °C and 15 s; annealing and
extension, 60 °C and 60 s). The primers for PB2 were as follows:
forward, 5-GCAGAACCCAACAGAAGAGC; reverse, 5-GCT-
GTTGCTCTTCTCCCAAC. The primers for GAPDH were as
follows: forward, 5-CTGGCGTCTTCACCACCATGG; reverse,
5-CATCACGCCACAGTTTCCCGG.The -fold change (2Ct)
was calculated according to Pfaffl (34). Expression levels were
analyzed using Western blotting. Blots were immunostained
using the following antibodies: monoclonal mouse anti-MxA
(35), monospecific rabbit anti-Mx1 (36), polyclonal rabbit anti-
NP,4 and polyclonal rabbit anti-GAPDH (Santa Cruz Biotech-
nology, catalog no. sc-25778).
vRNP Import Assay—Vero cells were transfected with either
pcDNA3.1()neo MxA or empty vector using Viafect (Pro-
mega). 24 h post-transfection, cells were pretreated with 10M
cycloheximide or solvent for 1 h at 37 °C. Then cells were
infected with FPV at m.o.i. 10 for 4 h in the presence of cyclo-
heximide or solvent. Cells were fixed with 3% paraformalde-
hyde and permeabilized using 0.5% Triton X-100. Cells were
stained using an affinity-purified polyclonal MxA antibody
(derived from rabbit serum against recombinantHis-MxA) and
amonoclonal NP antibody (catalog no. HB65, ATCC). Samples
4 D. A. Müller and J. Pavlovic, unpublished data.
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were mounted in DAPI containing mounting medium (Fluoro-
mount, Southern Biotech) and consequently analyzed by con-
focal laser-scanning microscopy (CLSM Leica SP5, Leica
Microsystems) using LAS AF software (Leica). Images were
assessed for nuclear import of vRNPs by counting MxA-ex-
pressing cells with a nuclear NP signal. Additionally, the NP
mean nuclear signal intensity ofMxA-expressing cells was ana-
lyzed using ImageJ software. Cells not expressing MxA were
used as a negative control for both analyses.
Co-immuno-precipitation—Co-immunoprecipitation was
either performed with pH1N1-NP(H5N1)- or rSC35M-in-
fected (m.o.i. 5) Vero cells transiently expressing MxA (wild
type or mutant) for 6 h or Vero cells co-transfected with
pcaggs-NP (Kan-1, pH1N1, or PR8) and pcDNA3.1()
neo-MxA (wild type or variant). In either case, cells were lysed
(20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM MgCl2, 100 nM
iodacetamide, 50 mMNaF, 1 mMNa3VO4, 1% Nonidet P-40, 50
mM -glycerophosphate, and Roche Complete protease inhib-
itor mixture) for 30 min in the dark on ice. Lysates were trans-
ferred on QiaShredder columns (Qiagen) and subsequently
centrifuged in a tabletop centrifuge at 13,000 g for 20 min at
4 °C. IAVNPwas immunoprecipitated from lysates with 0.5g
of anti-NP (HB65 supernatant, ATCC) on a rotating wheel at
4 °C overnight. To capture the complexes, magnetic protein G
Dynabeads (Invitrogen) were blocked with lysates of untreated
cells and then incubated with the immunoprecipitated lysates
on the rotating wheel for 3 h at 4 °C. Beads were washed six
times in washing buffer (20 mM Tris-HCl (pH 7.5), 150 mM
NaCl, 5 mM MgCl2, and 1% Nonidet P-40) while vortexing.
Bound protein was eluted in Laemmli buffer at 92 °C for 5 min.
Samples were analyzed by SDS-PAGE andWestern blot analy-
sis. Blots were stained for MxA (rabbit anti-Mx1, Novus Bio-
logicals, catalog no. H00004599_D01P), NP (rabbit anti-NP,
in-house), and GAPDH (rabbit anti-GAPDH, Santa Cruz Bio-
technology, catalog no. sc-25778).
Results
Oligomeric MxA Disassembles upon GTP Binding into
Tetramers and Dimers—To investigate whether MxA has to
first adopt a defined oligomeric or monomeric form to exert
antiviral activity against IAV,wemade use of severalmutants of
MxA that form complexes with a defined stoichiometry (Fig.
1A) (5, 12). First, we assessed whether GTP binding has an
influence on the oligomerization of recombinant wild-type
MxA and MxA interface mutants (Fig. 1A) using SEC-MALS
analysis. For this purpose, recombinant His-tagged MxA pro-
teins were expressed in bacteria and subsequently affinity-pu-
rified using nickel-agarose columns. The purificationwasmon-
itored by SDS-PAGE and Coomassie staining (Fig. 1B). The
activity of the purified proteins was then tested by measuring
their GTPase activity in dependence of their concentration
(Fig. 1C). With the exception of the G domain mutant
MxA(T103A), wild-type MxA as well as the MxA mutants
forming complexes with defined stoichiometry exhibited
GTPase activity in a very similar manner, as described in previ-
ous reports (5, 12). Subsequently, the oligomeric state of the
purified MxA protein complexes was assessed by SEC-MALS
analysis in the presence or absence of the non-hydrolysable
GTP analog GTPS (Fig. 1D). In the presence of 1 mM GTPS,
wild-type MxA disassembled from higher-ordered oligomeric
structures to tetramers and, to a small extent, also to dimers.
The hinge 1mutantMxA(R640A) shifted from a tetrameric to a
dimeric state. By contrast, in the presence of GTPS, the stalk
interface 1 and 2 mutants, dimeric MxA(L617D), and mono-
meric MxA(M527D) did not alter their stoichiometries (Fig.
1D). These data clearly demonstrate that GTP binding induced
purifiedMxA to disassemble fromhigher oligomeric structures
to tetramers and dimers. Similar data have been obtained pre-
viously for dynamin. Under low-salt conditions and in the pres-
ence of GTPS, preassembled dynamin is destabilized, forming
lower oligomeric structures (37). As expected, the addition of
GTPS did not lead to a stable dimerization of the monomeric
MxA(M527D) via the G domain.
Oligomeric MxA Accumulates in the Perinuclear Region of
Mammalian Cells—To assess whether the oligomerization of
MxA occurs at defined subcellular sites, we carried out the
split-GFP complementation assay as described previously using
HeLa cells and concomitantly immunostainedMxAwith a spe-
cificantibody (30).Asexpected,pairwiseco-transfectionofcon-
structs encoding split-GFP-MxA fusion proteins of wild-type
MxA, MxA(R640A), andMxA(L617D) led to pronounced GFP
signals indicative of the formation of dimers or higher-ordered
oligomers, whereas co-transfection of the constructs encoding
the split-GFP-MxA fusion proteins of the monomeric variant
MxA(M527D) did not exhibit any GFP signal. Wild-type MxA,
MxA(R640A), andMxA(L617D) accumulated in a pronounced
punctuate pattern in the perinuclear region (Fig. 2A). Parallel
immunostaining of the split-GFP-MxA fusion proteins with an
MxA-specific antibody revealed an identical distribution of the
MxA and GFP signals. This observation indicates that a very
high percentage of the fusion proteins is engaged in oligomer-
ic structures. The MxA-specific staining of split-GFP-MxA
(M527D) fusion protein revealed a diffuse, predominantly peri-
nuclear localization (Fig. 2A). Immunostaining of an untagged
version of wild-typeMxA andMxAmutants expressed in Vero
cells revealed amore dispersed distribution ofMxA in the cyto-
plasm. Because split-GFP complexes have to be stabilized by
incubation at 27 °C for 2 h to yield a detectable signal, we also
incubated the untagged version ofMxA under these conditions
before fixation. This led to a pronounced accumulation ofMxA
in dot-like structures (Fig. 2A). Therefore, it is conceivable that
the observed punctuate pattern of the split-GFP-MxA fusion
proteins is, at least in part, the result of incubation at 27 °C. As
reported previously, no significant MxA immunostaining or
GFP-MxA signal was detected in the nuclei (Fig. 2A) (6, 30).
In the next step, we assessed which stoichiometry wild-type
MxA and its interface or hinge 1 variants adopt in mammalian
cells using gel electrophoresis under non-denaturing condi-
tions. For this purpose, Vero cells were transfectedwith expres-
sion vectors encoding wild-type MxA, MxA(R640A), MxA
(L617D),MxA(M527D), and theGTPase-deficientMxA(T103A).
After 24 h, the cells were lysed under non-denaturing condi-
tions, and the lysates were subjected to non-denaturing PAGE
andWestern blot analysis using anMxA-specific antibody (Fig.
2B). The results revealed that most of the wild-typeMxA ran at
a molecular mass of300 kDa, indicating that it predominantly
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formed tetramers. Interestingly,MxA(T103A)deficient forGTP-
binding andhydrolysis also ran as a tetramer, suggesting that, in
mammalian cells,MxA assumes a tetrameric form independent
of GTP binding. The hinge 1 mutant MxA(R640A), however,
which exhibited a molecular mass of 140 kDa, appeared to
assemble into dimers. This contrasted with our observation
made with purified MxA(R640A), which assembled primarily
into tetramers in the absence of GTPS (Fig. 1D). As expected,
the interface variants MxA(L617D) and MxA(M527D) accu-
mulated as dimers and monomers, respectively (Fig. 2B). MxA
from lysates of IFN-induced A549 cells also separated as
tetramers, indicating that the stoichiometry of ectopically
expressed MxA protein complexes is comparable with the
endogenous protein (Fig. 2B). Incubation of extracts of MxA-
expressing cells with 1mMGTP or GTPS for 1 h at 4 °C before
separation on denaturing PA gels had no influence on the stoi-
chiometry ofMxA. Incubation at higher temperatures (25 °C or
37 °C) led to a rapid degradation ofMxAdespite the presence of
FIGURE 1. Purified humanMxAdisassembles into tetramers and dimers in the presence of GTPS. A, schematic of the humanMxA structure on the basis
of its crystal structure (5, 12). TheGTPase (G), middle (M), andGTPase effector (GE) domains; BSE; and interface and hinge regions are depicted. The stalk region
comprises themiddle andGTPase effector domains aswell as two entities of the BSE. Listed are themutations affecting the stoichiometry or GTPase activity of
human MxA. B, Coomassie-stained SDS-PAGE gel of purified His-tagged wild-type MxA and the indicated mutants with defined stoichiometry. C, GTPase
activity of the MxA wild type and the indicated mutants in dependence of their concentration (conc.). Data are represented as mean S.E. of duplicates. D,
analysis of self-assembly of purified wild-type MxA, MxA(R640A), MxA(L617D), and MxA(M527D) by MALS combined with size exclusion chromatography.
Elution profiles of the recombinant MxA proteins were monitored by absorption at 280 nm. Samples were analyzed in the absence (red line) or presence of 1
mM GTPS (blue line). The absolute molecular weights are depicted as black lines. The graphs are representative of two independent experiments. AU,
absorbance unit.
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a high concentration of protease inhibitors (data not shown).
Therefore, when expressed in mammalian cells, wild-type
MxA, and in particular also the hinge 1 mutant MxA(R640A),
adopted a similar stoichiometry as purified recombinant MxA
incubated with GTPS.
MxA Interface and Hinge 1 Mutants Exert Antiviral Activity
against IAV in a Dose-dependentManner—In the next step, we
evaluated whether the MxA interface and hinge 1 variants
restricted IAV infection. For this purpose, we transfected
HEK293T cells with plasmids encoding wild-type MxA, the
interface variants MxA(L617D) (dimer) and MxA(M527D)
(monomer), and the hinge 1 variant MxA(R640A) (dimer/te-
tramer) as well as the inactive MxA(T103A) and infected them
with the MxA-sensitive IAV strain pH1N1-NP (H5N1) at vari-
ous concentrations (18).The virus titerwasdeterminedbymea-
suring the TCID50 per milliliter directly on the cells expressing
wild-type MxA or MxA mutants, as outlined under “Experi-
mental Procedures.”Wild-typeMxA as well as all interface and
hinge 1 mutants exhibited a pronounced inhibition of IAV
growth (90%) compared with cells expressing the inactive
mutant MxA(T103A) (Fig. 3A). MxA expression control of the
transfected cells, depicted in Fig. 3B, showed that the antivirally
active variants of MxAwere not expressed at higher levels than
the positive and negative controls, wild-type MxA and
MxA(T103A), respectively. In addition, we tested the antiviral
activity of MxA complexes with defined stoichiometry using
the plasmid-based IAV minimal replicon reconstitution assay
of the A/Thailand/1/2004 (Kan-1) strain (Fig. 3C) (18). To that
end, we co-transfected plasmids encoding the components of
the viral replicase, the virus-dependent luciferase reporter
gene, and increasing amounts ofMxA-encoding plasmids (200,
400, and 800 ng of plasmid). The data clearly showed that the
tested MxA stalk interface 1 and 2 mutants as well as the BSE
hinge 1 variant strongly restricted the amplification of the lucif-
erase reporter gene in an expression level-dependent manner,
whereas MxA(T103A) had no effect, even at high expression
levels (Fig. 3, C and D). As reported previously (8, 12), the stalk
interface 3 mutant MxA(R408A) and MxA lacking the L4 loop
MxA(L4) showed no antiviral activity, even at very high
expression levels (data not shown). Most likely, mutation of
MxA at residue Arg-408 not only prevents higher-order oligo-
merization but also disturbs a region that is essential for its
antiviral function, and the L4 loop appears to be important for
the interaction with the NP of IAV (8, 9, 12). Taken together,
the data clearly demonstrate that dimeric as well as monomeric
forms of MxA exhibited a pronounced antiviral activity, con-
firming that MxA assembly into higher-ordered oligomers is
not a prerequisite for restricting IAV replication.
MxA Inhibits IAV Replication at a Step After Primary
Transcription—We have shown previously that MxA inhibits
replication of avian IAV in mouse cells at a cytoplasmic step
following primary transcription of viral mRNAs (28). To verify
that MxA also inhibits IAV replication in human cells at a step
occurring after primary transcription, we infected cyclohexim-
ide-treated or untreated HEK293T cells expressing wild-type
MxA,MxA(R640A),MxA(L617D),MxA(M527D),MxA(T103A),
wild-type mouse Mx1 (mMx1), or the inactive mMx1(K49A)
for 6 h with pH1N1-NP(H5N1) and performed RT qPCR anal-
yses from isolated RNA with PB2-specific primers (Fig. 4A).
mMx1 served as a positive control for the inhibition of primary
transcription (Fig. 4A) (28). The data clearly show that, in
cycloheximide-treated cells, wild-type MxA andMxAmutants
forming complexes with defined stoichiometry did not affect
primary transcription of IAV, whereas mouse Mx1, known to
inhibit primary transcription, reduced the level of PB2 mRNA
to less than 30%. As expected, the inactive Mx1(K49A) mutant
exhibited no effect on the primary transcription of IAV. The
activity of cycloheximide was verified in the same experiment
byWestern blotting (Fig. 4B). In the absence of cycloheximide,
all antivirally active variants of MxA as well as mMx1 reduced
the levels of PB2 mRNA to 50% of the inactive controls
MxA(T103A) and mMx1(K49A).
Next we monitored the nuclear import of IAV vRNPs into
the nucleus of infected cells in the presence or absence of MxA
expression. To make sure that no other IFN-induced effector
protein was interfering with the assay, we utilized Vero cells
lacking IFN type I genes. We infected Vero cells ectopically
expressing wild-type MxA in the presence of cycloheximide
with m.o.i. 10 of fowl plague virus (FPV, H7N7) and analyzed
the nuclear import of vRNP by immunofluorescence micros-
copy using antibodies specific for IAV NP and MxA. FPV was
chosen because of its high sensitivity to MxA (36) and efficient
translocation of incoming vRNP into the nucleus.5 As shown in
Fig. 4, C–E, we were not able to detect any retention of the
vRNPs in the cytoplasm when MxA was present. Images were
assessed for nuclear import of vRNPs by counting MxA-ex-
pressing cells with a nuclear NP signal (Fig. 4D) or measuring
the NP mean nuclear signal intensity of MxA-expressing cells
(Fig. 4E). Cells transfected with empty vector were used as a
negative control (Fig. 4, D and E). Taken together, these data
demonstrate that human MxA does not interfere with the
nuclear import of vRNPs and that it inhibits IAV replication at
a step that follows primary transcription.
Overexpression of NP Interferes with the Antiviral Function of
Human MxA—We and others have shown previously that
overexpression of PB2 and NP interfered with the antiviral
function of mouse Mx1 (15–17). Therefore, we next wanted to
test whether the activity of MxA could be overcome by
increased expression of NP and/or PB2. For this purpose, we
5 P. E. Nigg and J. Pavlovic, unpublished data.
FIGURE2.HumanMxAself-assembles into tetramers in thecytoplasm.A, splitGFPcomplementationassaywith split-GFP-MxA fusionproteins inHeLa cells.
Constructs encoding the indicated split-GFP-MxA fusionproteinswere co-transfected. Twenty-four hours post-transfection, the cellswere transferred to 27 °C,
incubated for another 2 h, and fixated. MxA was immunostained with a mouse monoclonal antibody directed against MxA. Only dimeric or oligomeric forms
ofMxA yielded aGFP signal. The images shownare representative of three independent experiments.w/o, without. B, Western blot analysis of non-denaturing
PAGEof lysates fromVero cells transiently transfectedwith plasmids encoding the indicatedMxA variants or fromA459 cells either stimulatedwith IFNor left
untreated. Immunostaining was performed with a rabbit polyclonal antibody directed against MxA. The molecular weights and the positions of the marker
proteins used (nativeMARK, Invitrogen) are indicated. The Western blot shown is a representative of three independent experiments.
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made use of the IAV minimal replicon reconstitution assay in
HEK293T cells either expressing wild-type MxA or the GTP
binding-deficient mutant MxA(T103A). The level of wild-type
MxA and MxA(T103A) expression was first adjusted to a level
yielding50% to 70% inhibition of IAV polymerase activity by
wild-type MxA compared with MxA(T103A) (Fig. 5, A and B).
As a control, we employed mouse wild-type Mx1 and its inac-
tivemutantMx1(K49A) (Fig. 5,C andD). To assess whetherNP
or PB2 interferes with the MxA-mediated inhibition, gradually
increasing amounts of plasmids encoding either PB2 (10–320
ng) or NP (50–1600 ng) were added to constant amounts of
plasmids encoding MxA or MxA(T103A). To assess the inter-
ference of NP or PB2 with the activity of humanMxA ormouse
Mx1, the values (normalized for transfection efficiency)
obtained for MxA or Mx1 were divided by the corresponding
values for MxA(T103A) or Mx1(K49A) and expressed as per-
centage inhibition relative to the inactive mutants. For MxA,
the results revealed that only increasing amounts of NP led
to interference with the MxA activity, whereas increasing
amounts of PB2 had no effect (Fig. 5, A and B). By contrast,
overexpression of NP as well as PB2 interfered with the activity
ofmouseMx1 (Fig. 5,C andD). Therefore, at least in this exper-
FIGURE 3.MxA mutants with defined stoichiometry inhibit IAV replication. A, HEK293T cells transiently expressing wild-type MxA or the indicated MxA
mutants were infectedwith the IAV strain pH1N1-NP (H5N1) as detailed under “Experimental Procedures.” Viral titers represented as TCID50 permilliliter were
determineddirectly onHEK293T cells expressing the indicatedMxAmutants. TCID50permilliliterwasdetermined fromtriplicates.B,Westernblot analysis from
lysates of cells expressing the indicatedMxAvariants used for viral titer determination shown inA.C, minimal replicon reconstitution assay. HEK293T cellswere
co-transfected with plasmids coding for the IAV proteins PB1, PB2, PA, and NP together with a reporter construct encoding firefly luciferase under the control
of an IAV promoter and wild-type MxA or the indicated MxAmutants. Increasing amounts of plasmids encoding wild-type MxA or MxAmutants were added.
White columns, 200 ng; gray columns, 400 ng; black columns, 800 ng. A and C, data are represented asmean S.E. of triplicates (Student’s t test; **, p	 0.05).D,
Western blot analysis of lysates from theminimal replicon reconstitution assays shown in B. Immunostaining was performedwith antibodies directed against
the indicated proteins. IFN, control of endogenous MxA expressed in A549 cells in response to induction with IFN; conc., concentration.
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FIGURE 4.MxA inhibits IAV replication at a step following primary transcription. A, RT qPCR analysis of IAV PB2 mRNA in IAV pH1N1-NP-infected (H5N1)
cells transiently expressing the indicated human MxA variants, mouse wild-type Mx1 (mMx1), or its inactive mutant Mx1(K49A). The cells were either treated
with cycloheximide (CHX, black columns) or with EtOH as a solvent control (white columns). All experiments were performed in triplicate. The data are
represented asmean S.E. B, Western blot analysis of lysates used for RT qPCR shown in A. Immunostainingwas performed using antibodies directed against
the indicated proteins. C–E, immunofluorescence analyses of nuclear import of incoming vRNPs. Vero cells transfected either with a plasmid encoding
wild-typeMxAor empty vectorwere infectedwith FPV (H7N7) in the presence of cycloheximide at 10m.o.i. for 4 h. vRNPs andMxAwere immunostained using
antibodies directed against NP andMxA. C, confocal laser-scanningmicroscopy images. Red, NP; green, MxA; blue, DAPI. Shown are representative images. The
experiment was performed in biological duplicates. 50 cells/replicate were recorded.D, nuclear import of vRNPs was assessed by counting NP-positive nuclei
of images recorded in C. n.s., not significant. E, quantification of vRNP import by NP mean nuclear signal intensity of images recorded in C. The data are
represented as mean S.E. D and E, Student’s t test, p	 0.05.
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imental setup, MxA appeared to target only NP, whereas Mx1
appeared to functionally interact with both NP and PB2, as
described previously. The increased values obtained in samples
with a high concentration of NP independent of MxA or Mx1
are the result of enhanced replication efficiency of the mini
replicon (Fig. 5, B and D) in the presence of a high concentra-
tion of NP.
Dimeric Variants of MxA Interact with NP Independent of
Other Viral Proteins—Despite the fact that, so far, experimental
evidence for a physical interaction of human MxA with NP is
lacking, the available data strongly suggest a functional rela-
tionship between these two proteins (18, 19, 33) (Fig. 5B). On
the basis of our observations that GTP binding led to a disas-
sembly of MxA from higher-ordered oligomers to tetramers
and dimers that efficiently blocked IAV replication, we wanted
to test whether MxA variants forming complexes with defined
stoichiometry would exhibit a higher affinity to NP than wild-
typeMxA. For this purpose, we carried out co-immunoprecipi-
tation assays.We transfectedVero cellswith plasmids encoding
wild-typeMxA,MxA(R640A),MxA(L617D),MxA(M527D), or
MxA(T103A) and subsequently infected them for 6 h with the
IAV strains pH1N1-NP(H5N1) or rSC35M, both highly sensi-
tive to the activity of MxA. Immunoprecipitation of NP
revealed that both dimer-forming variants, the hinge 1 mutant
MxA(R640A), aswell as the interfacemutantMxA(L617D) effi-
ciently co-precipitated with NP. Wild-type MxA, the mono-
meric variant MxA(M527D), and the GTP binding-deficient
mutant MxA(T103A) exhibited no or only a barely detectable
interaction with NP (Fig. 6A). Therefore, these data strongly
support our model that oligomeric MxA has first to be con-
verted into dimers to efficiently bind to NP. Because NP exists
in a vRNP-bound form as well as in an unbound form in
infected cells, we assessed in a next step whetherMxA is able to
interact with ectopically expressed NP in the absence of any
additional viral component. Therefore, we co-transfected plas-
mids encoding wild-type MxA, MxA(R640A), MxA(L617D),
MxA(M527D), or MxA(T103A) with plasmids encoding NP
either derived from a highly Mx-sensitive avian IAV strain
(Kan-1) or two MxA-resistant strains (A/Hamburg/4/2009
(pH1N1) and A/PR/8/34 strain (PR8)). The NP of the MxA-
sensitive strain efficiently co-precipitated with the two dimeric
variants of MxA (Fig. 6B), corroborating the findings observed
with IAV infection (Fig. 6A).We also observed co-immunopre-
cipitation of dimeric forms ofMxAwith NP of theMxA-resist-
ant strains p(H1N1) and PR8, although to a lesser extent than
with the NP of Kan-1 (Fig. 6B).
FIGURE5.OverexpressionofNPbutnotPB2 interfereswith theantiviral activityofMxA.A andB, plasmids encodingwild-typeMxAor the inactivemutant
MxA(T103A) were co-transfectedwith increasing amounts of plasmids encoding (A) PB2 (10, 20, 40, 80, 160, or 320 ng) or (B) NP (50, 100, 200, 400, 800, or 1600
ng) together with the plasmids of the minimal replicon reconstitution assay derived from an H5N1 virus. RLU, relative light units. C and D, plasmids encoding
wild-type mouse Mx1 or Mx1(K49A) were co-transfected with increasing amounts of plasmids encoding PB2 (C) or NP (D) (see A and B) together with the
plasmids of the minimal replicon reconstitution assay derived from an H5N1 virus. The number given below each column pair represents the percentage of
inhibition of the polymerase activity by wild-type MxA or Mx1 compared with the corresponding values in the presence of the respective inactive mutant,
MxA(T103A) or Mx1(K49A). The experiment was performed in biological triplicates, and the data are represented as mean S.E.
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Discussion
The human MxA protein restricts the replication of a broad
variety of negative- and positive-stranded RNA viruses as well
as DNA viruses. Besides their different genomes, these viruses
replicate at different subcellular locations, employing different
replication strategies. Therefore, MxA either interferes with
viral replication via a general, rather nonspecific mechanism
affecting many different viruses, or MxA has developed differ-
ent molecular mechanisms to block virus replication.
Although, for some viruses, such as IAV, Thogotovirus, and La
Crosse virus, the replication steps and/or viral targets inhibited
by MxA have been identified, for most MxA-restricted viruses
the mode of action or the viral targets remain undetermined.
Usingmurine 3T3 cells, we have shown previously thatMxA
inhibits IAV replication at a step occurring after primary tran-
scription. Synthesis of primary transcripts of the polymerase
subunits, hemaglutinin, neuraminidase, and NP are unaffected
byMxA, whereas, surprisingly, the production of primary tran-
scripts of NS1 and M1 is increased 2- to 3-fold. The primary
transcripts are exported efficiently and have the capacity to be
translated in vitro (28). However, when translocated to the
nucleus by means of an N-terminal nuclear localization
sequence, MxA efficiently blocks primary transcription of IAV
(7). We now observed very similar results in human cells.
Ectopic expression of MxA restricted IAV replication without
affecting the nuclear import of incoming vRNPs (Fig. 4). In
addition, our RT qPCR data obtained from mRNA isolated
from HEK293T MxA-expressing cells infected with IAV
revealed that, in the presence of MxA, primary transcription of
PB2 mRNA is not blocked (Fig. 4A). Xiao et al. (39) have
reported recently that MxA interferes with IAV replication at
two distinct stages, a step prior to primary transcription
together with an unknown IFN-induced protein and a step fol-
lowing primary transcription. In our study, we focused only on
the second step and analyzed the antiviral function of MxA in
the absence of other IFN-induced effector proteins known to
inhibit IAV entry and uncoating, such as IFITMs (40).
Mx proteins have the capacity to assemble into oligomeric
structures of various complexities. In vitro, MxA protein
assembles into tetramers (12) and has the capacity to assume
higher-ordered oligomeric structures by forming rings or heli-
cal filaments (41, 42). Moreover, on the basis of the crystal
structure, Gao et al. (5, 12) have proposed that MxA assembles
into ring-like structures. The question whether monomeric
FIGURE 6.Dimeric formsofMxA formstable complexeswithNP.A, Vero cellswere transfectedwith plasmids encoding the indicatedMxAvariants and then
infected for 6 h with m.o.i. 5 of IAV strain pH1N1-NP(H5N1) (left panel) or IAV strain rSC35M (right panel). NP was immunoprecipitated (IP) from lysates using a
mousemonoclonal NP-specific antibody, and the resulting complexes were subjected toWestern blot analyses using polyclonal rabbit antibodies specific for
MxA andNP. In addition, input samples (whole cell lysates,WCL) alsoweremonitored for expression ofMxA, NP, andGAPDH (loading control) byWestern blot
analysis. B, Vero cells were co-transfected with plasmids encoding the indicated MxA variants together with plasmids encoding NP from the indicated IAV
strains. Immunoprecipitation of NP and Western blot analyses of immunoprecipitated proteins and whole cell lysates were performed as described in A.
Immunostaining of the Western blots was performed with antibodies against MxA, NP, or GAPDH. The Western blots shown are representative of three
independent experiments.
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and/or oligomeric forms of MxA exert their antiviral activity
against IAV and other viruses remains an unsolved issue. Sev-
eral previous studies have demonstrated that the monomeric
mutant MxA(L612K) efficiently restricts IAV, Thogotovirus,
and vesicular stomatitis virus (6, 25, 27). However, Gao et al. (5,
12) have reported recently that dimeric and monomeric inter-
face and hinge mutants of MxA failed to exhibit antiviral activ-
ity against IAV and La Crosse virus using a minimal replicon
reconstitution assay for IAV or an N sequestration assay for La
Crosse virus, respectively. On the basis of their findings, Gao et
al. (5) have proposed a model in which MxA would assemble
into oligomeric rings around incoming vRNPs of IAV. The
major caveat of thismodel, however, is the fact thatMxA inhib-
its IAV replication after the nuclear import of viral RNPs and
after primary transcription of viralmRNAs has taken place (Fig.
4) (7, 28). Therefore, we re-evaluated the antiviral activity of the
dimeric andmonomeric variants ofMxA (plasmids provided by
Georg Kochs) by performing infection experiments with IAV.
Intriguingly, dimeric MxA variants with mutations in the stalk
interface 1 or BSE hinge region as well as the monomeric inter-
face 2 mutant efficiently restricted IAV, indicating that MxA
does not necessarily have to assemble into higher oligomeric
structures to exert antiviral activity against IAV.On the basis of
the same minimal replicon reconstitution assay we used in this
study (Fig. 3C), Gao et al. (5, 12) have shown previously that the
MxA variants forming complexes with defined stoichiometry,
MxA(R640A),MxA(L617D), andMxA(M527D), do not restrict
IAV replication. However, they adjusted the amount of MxA
expression to a level where wild-type MxA only reduced the
activity of the IAV polymerase complex to 70–80% of the neg-
ative control. In fact, we obtained very similar results at low
expression levels of MxA proteins (Fig. 3C).
The question of whether GTP promotes oligomerization or
disassembly of MxA oligomers remains an issue of debate.
Clearly, oligomerization of purified MxA is highly salt-depen-
dent (41). Here we observed that, in the absence of GTP under
medium salt conditions (200 mM KCl), purified recombinant
MxA formed higher-order oligomers that, upon addition of
GTPS, disassembled primarily into tetramers and, to a lower
extent, also into dimers. Similarly, Kochs et al. (41) have dem-
onstrated previously that, under high-salt conditions (300 mM
NaCl), MxA exists predominantly in a lower oligomeric, non-
sedimentable form. Addition of GTPS does not increase the
sedimentable fraction of MxA, indicating that GTPS does not
mediate oligomerization. By contrast, Gao et al. (5, 12) have
reported recently that, under the same experimental condi-
tions, the non-sedimentable fraction of MxA converts into a
sedimentable oligomeric structure. The authors explained their
observationwith the generation of an additional nucleotide-de-
pendent interphase in the G domain (5). However, recent evi-
dence indicates thatGTP-dependentGdomain dimerization of
MxA is a transient process that cannot be stabilized by GTPS
(13). Under low-salt conditions, MxA forms predominantly
condensed oligomeric and sedimentable structures that, in the
presence of GTPS, rearrange into spiral or stack-like forms
(41). In the case of dynamin, preassembled sedimentable oligo-
mers convert into lower oligomeric, non-sedimentable struc-
tures in the presence of GTPS (37).
In vitro, the hinge 1 mutant MxA(R640A) predominantly
formed tetramers that converted into dimers in the presence of
GTPS (Fig. 1B). Gao et al. (5) have purified recombinant
MxA(R640A) predominantly in the form of dimers, even in the
absence of GTPS, but in the presence of substantially higher
salt concentrations (400 mM) . Therefore, it is conceivable that,
for MxA(R640A) like for wild-type MxA, the stoichiometry of
these recombinant proteins is not only a function of GTP but
also strongly dependent on salt concentration.
Non-denaturing PAGE analyses of MxA expressed endoge-
nously or ectopically in human cells revealed that wild-type
MxA accumulated primarily in a tetrameric form. The reason
why MxA(R640A), in our hands, runs predominantly as a
tetramerwhen affinity-purified but as a dimerwhen analyzed in
lysates of mammalian cells is not entirely clear, but it might be
due to the presence of GTP and/or accessory proteins in the
cellular context. Taken together, wild-type MxA appears to
exist primarily as tetramer in the cytoplasm of infected cells
and, at least in vitro, has the capacity to disassemble into dimers
in a GTP-dependent fashion. The fact that the dimeric forms
MxA(R640A) andMxA(L617D) exert antiviral activity strongly
suggests that the GTP-dependent formation of dimers is
important for the function of MxA. In this context, it is inter-
esting to note that human MxB (Mx2), shown recently to
restrict human immunodeficiency virus, appears to act as a
dimer, albeit in a GTP-independent manner (43–45).
The observation that predominantly dimeric forms of MxA
have the capacity form stable complexes with NP in infected
cells lends further support to our hypothesis that dimers play a
pivotal role for the activity of MxA. The fact that MxA dimers
also formed a complex with ectopically expressed NP from a
highly Mx-sensitive avian H5N1 strain in the absence of any
other viral component demonstrates that MxA can interact
withNP that is not boundwithin the vRNP.Wild-typeMxAdid
not form a complex with NP at detectable levels, even when the
cells were infected with a highly MxA-sensitive virus (Fig. 6A).
A possible explanation for this observationmay be that, follow-
ing infection with IAV, only small amounts of MxA are disas-
sembled into dimers to interact with NP. The major part of
MxA could then remain in higher-ordered oligomeric struc-
tures. Alternatively, it may be possible that the high affinity of
theMxAdimer toNP is only required for the initial recognition
of NP. After the initial interaction, MxA could convert again
into higher oligomeric structures exhibiting a low affinity for
NP. In vitroNP is known to form oligomers even in the absence
of RNA (46). Therefore, it may be possible that MxA reoli-
gomerizes around newly synthesized NP oligomers, thereby
inhibiting its function. In the case of the antivirally activemono-
meric form ofMxA,MxA(M527D), it is conceivable that a low-
affinity interaction to NP is sufficient for antiviral activity in
certain assays. Alternatively, the transient G domain dimeriza-
tion stimulated by GTP binding (13) could also result in a tran-
siently increased affinity forNP thatmay be sufficient to disrupt
binding of NP to UAP56.
Testing the interaction ofNPs from two distinctMxA-resist-
ant strains revealed that NP from the 2009 pandemic H1N1
strain (pH1N1) was still capable of interacting with MxA,
whereas NP from the PR8 strain (a derivative of the 1918H1N1
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strain) showed reduced complex formation. Interestingly, these
twoIAVstrainsdevelopedtheirMxAresistancephenotypeinde-
pendently of each other (19) and, therefore, introduced distinct
adaptive mutations into their NP coding sequence. These find-
ings led us to the conclusion that there are at least two mecha-
nisms for IAV to evade restriction by MxA. For the PR8 strain,
this entailsminimizing the affinity toMxA,whereas the pH1N1
strain employed a different strategy, possibly by reducing the
affinity to an MxA-associated protein such as UAP56 (30).
Whether MxA interacts directly with NP or via the MxA-
associated UAP56 remains to be determined. Of course, it is
possible thatMxA restricts the replication of viruses other than
IAV by oligomerizing into ring-like structures around nucleo-
capsids, “strangling” them in a dynamin-like fashion by GTP-
dependentmechanical constriction (13). However, on the basis
of our data presented here, we propose a newmodel inwhich, in
response to IFN induction, MxA is synthesized and assembled
into higher oligomeric structures, possibly partially associated
with membranes of the smooth endoplasmic reticulum (38).
These oligomeric structures may represent a preactive form of
MxA. In infected cells, a still undefined viral component would
then trigger a GTP-driven disassembly of oligomeric MxA into
dimers, allowing the association with newly synthesized NP
translated from primary transcripts. Therefore, sequestration
of NP from replication sites in the nucleus may represent the
long sought after mechanism of MxA action against IAV.
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